Quality of life of patients with La Peyronie's disease undergoing local iontophoresis therapy: A longitudinal observational study


Submitted: November 12, 2021
Accepted: December 21, 2021
Published: March 29, 2022
Abstract Views: 638
PDF: 385
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Tatiana Bolgeo SC Infrastructure Research Training Innovation, Department of Integrated Activities Research Innovation, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
  • Roberta Di Matteo SC Infrastructure Research Training Innovation, Department of Integrated Activities Research Innovation, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
  • Menada Gardalini SC Infrastructure Research Training Innovation, Department of Integrated Activities Research Innovation, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
  • Denise Gatti SC Infrastructure Research Training Innovation, Department of Integrated Activities Research Innovation, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
  • Antonio Maconi SC Infrastructure Research Training Innovation, Department of Integrated Activities Research Innovation, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
  • Carmelo Boccafoschi City of Alessandria Clinic Monza Polyclinic, Alessandria, Italy.

Objectives: La Peyronie's disease tends to be underdiagnosed and undertreated. In Italy it affects about 7% of the population aged between 50 and 70 years old. The aim of this study is to evaluate the quality of life of patients undergoing iontophoretic therapy with verapamil and treatment outcomes at a two-year interval.
Materials and methods: This study evaluated 128 patients subjected to treatment cycles over a period of two years. Questionnaires were administered to the patients at the beginning and end of each cycle of iontophoretic therapy in order to monitor the degree of presumed anxiety, depression, pain and the associated quality of life.
Result: This prospective descriptive observational study included 128 patients aged between 42 and 74 years presenting pain during erection and/or coital intercourse, which ceased in 108 cases, diminished in 12 and remained present in 4. Concerning the penile deviation, which was present in all patients (128 cases), it disappeared in 6 cases, regressed in 90 cases, while it remained unchanged in 32 cases. As for the plaque consistency on palpation, in 42 patients the plaque was no longer present, in 50 cases the consistency diminished, while in 36 patients it remained unchanged. None of the cases evidenced an aggravation of the clinical condition. 57% of the evaluated patients had high levels of anxiety in the first cycle of iontophoretic sessions and low levels of depression. Anxiety decreased in 32% of cases. Depression was not related to pain but to sexual dysfunction. About 80 % of the patients assessed had an increase in quality of life at the end of the two-year follow-up.
Conclusions: In conclusion, it can be claimed that iontophoresis combined with verapamil therapy can improve patients' quality of life and offer them psychophysical well-being and an acceptable sexual relationship, thus decreasing anxiety and depression levels.


Mulhall JP, Alex B, Choi JM. Predicting delay in presentation in men with Peyronie’s disease. J Sex Med. 2010;7:2226-30. DOI: https://doi.org/10.1111/j.1743-6109.2010.01785.x

Paulis G, Romano G, Paulis L, Barletta D. Recent Pathophysiological Aspects of Peyronie’s disease: role of free radicals, rationale, and therapeutic implications for antioxidant treatment-literature review. Adv Urol. 2017; 2017:4653512. DOI: https://doi.org/10.1155/2017/4653512

Di Maida F, Cito G, Lambertini L, et al. The natural history of Peyronie’s disease. World J Mens Health. 2021; 39:399-405. DOI: https://doi.org/10.5534/wjmh.200065

La Pera G, Pescatori ES, Calabrese M, et al. Peyronie’s disease: prevalence and association with cigarette smoking. A multicenter population-based study in men aged 50-69 years. Eur Urol. 2001;40:525-30. DOI: https://doi.org/10.1159/000049830

Bivalacqua TJ, Purohit SK, Hellstrom WJ. Peyronie’s disease: advances in basic science and pathophysiology. Curr Urol Rep. 2000;1:297-301. DOI: https://doi.org/10.1007/s11934-000-0010-8

Dibenedetti DB, Nguyen D, Zografos L, et al. A population-based study of Peyronie’s disease: prevalence and treatment patterns in the United States. Adv Urol. 2011; 2011:282503. DOI: https://doi.org/10.1155/2011/282503

Montorsi F, Salonia A, Guazzoni G, et al. Transdermal electromotive multi-drug administration for Peyronie’s disease: preliminary results. J Androl. 2000; 21:85-90.

Trost LW, Gur S, Hellstrom WJG. Pharmacological management of Peyronie’s disease. Drugs. 2007; 67:527-45. DOI: https://doi.org/10.2165/00003495-200767040-00004

Coyne KS, Currie BM, Thompson CL, Smith TM. The test-retest reliability of the Peyronie’s disease questionnaire. J Sex Med. 2015;12:543-8. DOI: https://doi.org/10.1111/jsm.12769

Coyne KS, Currie BM, Thompson CL, Smith TM. Responsiveness of the Peyronie’s Disease Questionnaire (PDQ). J Sex Med. 2015;12:1072-9. DOI: https://doi.org/10.1111/jsm.12838

Bolgeo, T., Di Matteo, R. ., Gardalini, M., Gatti, D., Maconi, A., & Boccafoschi, C. (2022). Quality of life of patients with La Peyronie’s disease undergoing local iontophoresis therapy: A longitudinal observational study. Archivio Italiano Di Urologia E Andrologia, 94(1), 75–79. https://doi.org/10.4081/aiua.2022.1.75

Downloads

Download data is not yet available.

Citations